TNGX insider transaction filings

Tango Therapeutics, Inc. — 41 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-05. Screen TNGX transaction legs live →

FiledFormInsiderReported transactionsSource
2026-08-054Crystal Adam — President, R&DOption exercise (M): 27,000 @ $5.20 · Sale (S): 5,267 @ $26.79 · Sale (S): 21,733 @ $27.35 · Option exercise (M): 27,000 (derivative) @ $0EDGAR
2026-07-024Crystal Adam — President, R&DOption exercise (M): 27,000 @ $5.20 · Sale (S): 19,629 @ $29.34 · Sale (S): 7,371 @ $30.25 · Option exercise (M): 27,000 (derivative) @ $0EDGAR
2026-06-234Azelby Robert — DirectorGrant/award (A): 5,740 @ $0 · Grant/award (A): 35,910 (derivative) @ $0EDGAR
2026-06-084Ketchum John B — DirectorGrant/award (A): 4,000 @ $0 · Grant/award (A): 25,000 (derivative) @ $0EDGAR
2026-06-084Rothenberg Mace — DirectorGrant/award (A): 4,000 @ $0 · Grant/award (A): 25,000 (derivative) @ $0EDGAR
2026-06-084Lee Sung — DirectorGrant/award (A): 570 @ $0 · Grant/award (A): 3,570 (derivative) @ $0EDGAR
2026-06-084Calhoun Lesley Ann — DirectorGrant/award (A): 4,000 @ $0 · Grant/award (A): 25,000 (derivative) @ $0EDGAR
2026-06-034Crystal Adam — President, R&DOption exercise (M): 27,000 @ $5.20 · Sale (S): 6,140 @ $22.25 · Sale (S): 20,860 @ $23.06 · Option exercise (M): 27,000 (derivative) @ $0EDGAR
2026-05-054Crystal Adam — President, R&DOption exercise (M): 27,000 @ $5.20 · Sale (S): 25,900 @ $21.19 · Sale (S): 1,100 @ $22.00 · Option exercise (M): 27,000 (derivative) @ $0EDGAR
2026-05-054Gall Matthew — Chief Financial OfficerGrant/award (A): 40,000 @ $0 · Grant/award (A): 240,000 (derivative) @ $0EDGAR
2026-05-014Lee Sung — DirectorGrant/award (A): 12,300 @ $0 · Grant/award (A): 5,200 (derivative) @ $0EDGAR
2026-04-164Crystal Adam — President, R&DOption exercise (M): 38,460 @ $5.20 · Sale (S): 38,460 @ $25 · Option exercise (M): 38,460 (derivative) @ $0EDGAR
2026-04-024Crystal Adam — President, R&DOption exercise (M): 27,000 @ $5.20 · Sale (S): 27,000 @ $21.20 · Option exercise (M): 27,000 (derivative) @ $0EDGAR
2026-03-274Crystal Adam — President, R&DOption exercise (M): 12,000 @ $5.20 · Sale (S): 12,000 @ $20.11 · Option exercise (M): 12,000 (derivative) @ $0EDGAR
2026-03-094Crystal Adam — President, R&DSale (S): 20,251 @ $15EDGAR
2026-02-274Crystal Adam — President, R&DSale (S): 54,345 @ $12.77EDGAR
2026-02-044Crystal Adam — President, R&DGrant/award (A): 47,460 @ $0 · Sale (S): 18,251 @ $12.26 · Sale (S): 201 @ $12.90 · Grant/award (A): 284,760 (derivative) @ $0EDGAR
2026-02-044Weber Barbara — Director, Executive Chair, DirectorGrant/award (A): 37,522 @ $0 · Sale (S): 30,186 @ $12.26 · Sale (S): 333 @ $12.90 · Grant/award (A): 222,132 (derivative) @ $0EDGAR
2026-02-044Beckman Daniella — Chief Financial OfficerGrant/award (A): 44,330 @ $0 · Sale (S): 10,204 @ $12.26 · Sale (S): 113 @ $12.90 · Grant/award (A): 265,980 (derivative) @ $0EDGAR
2026-01-124Peters Malte — President & CEO, DirectorGrant/award (A): 350,000 @ $0 · Grant/award (A): 1,650,000 (derivative) @ $0EDGAR
2026-01-064Lee Sung — DirectorGrant/award (A): 10,000 @ $0 · Grant/award (A): 60,000 (derivative) @ $0EDGAR
2025-11-044Peters Malte — DirectorGrant/award (A): 150,000 (derivative) @ $0EDGAR
2025-10-274Third Rock Ventures IV, L.P. — 10% owner
Third Rock Ventures GP IV, L.P. — 10% owner
TRV GP IV, LLC — 10% owner
Sale (S): 477,401 @ $10.15EDGAR
2025-09-294Third Rock Ventures IV, L.P. — 10% owner
Third Rock Ventures GP IV, L.P. — 10% owner
TRV GP IV, LLC — 10% owner
Sale (S): 500,000 @ $8.02EDGAR
2025-09-174Third Rock Ventures IV, L.P. — 10% owner
Third Rock Ventures GP IV, L.P. — 10% owner
TRV GP IV, LLC — 10% owner
Sale (S): 363,541 @ $7.04EDGAR
2025-09-094Third Rock Ventures IV, L.P. — 10% owner
Third Rock Ventures GP IV, L.P. — 10% owner
TRV GP IV, LLC — 10% owner
Sale (S): 642,906 @ $7 · Sale (S): 86,459 @ $7.04EDGAR
2025-08-264Third Rock Ventures IV, L.P. — 10% owner
Third Rock Ventures GP IV, L.P. — 10% owner
TRV GP IV, LLC — 10% owner
Sale (S): 302,194 @ $7EDGAR
2025-08-214Third Rock Ventures IV, L.P. — 10% owner
Third Rock Ventures GP IV, L.P. — 10% owner
TRV GP IV, LLC — 10% owner
Sale (S): 1,100,000 @ $7.01EDGAR
2025-06-094Peters Malte — DirectorGrant/award (A): 6,250 @ $0 · Grant/award (A): 37,500 (derivative) @ $0EDGAR
2025-06-094Rothenberg Mace — DirectorGrant/award (A): 6,250 @ $0 · Grant/award (A): 37,500 (derivative) @ $0EDGAR
2025-06-094Ketchum John B — DirectorGrant/award (A): 6,250 @ $0 · Grant/award (A): 37,500 (derivative) @ $0EDGAR
2025-06-094Calhoun Lesley Ann — DirectorGrant/award (A): 6,250 @ $0 · Grant/award (A): 37,500 (derivative) @ $0EDGAR
2025-06-094Borisy Alexis — DirectorGrant/award (A): 6,250 @ $0 · Grant/award (A): 37,500 (derivative) @ $0EDGAR
2025-02-064Barry Douglas — General CounselSale (S): 2,774 @ $2.99 · Sale (S): 2,556 @ $3.16EDGAR
2025-02-064Crystal Adam — See RemarksSale (S): 7,432 @ $2.99 · Sale (S): 6,851 @ $3.16EDGAR
2025-02-064Weber Barbara — Chief Executive Officer, DirectorSale (S): 9,778 @ $2.99 · Sale (S): 9,013 @ $3.16EDGAR
2025-02-064Beckman Daniella — Chief Financial OfficerSale (S): 4,284 @ $2.99 · Sale (S): 3,948 @ $3.16EDGAR
2025-02-054Crystal Adam — See RemarksGrant/award (A): 53,015 @ $0 · Grant/award (A): 318,090 (derivative) @ $0EDGAR
2025-02-054Barry Douglas — General CounselGrant/award (A): 27,363 @ $0 · Grant/award (A): 164,175 (derivative) @ $0EDGAR
2025-02-054Weber Barbara — Chief Executive Officer, DirectorGrant/award (A): 105,875 @ $0 · Grant/award (A): 635,250 (derivative) @ $0EDGAR
2025-02-054Beckman Daniella — Chief Financial OfficerGrant/award (A): 26,119 @ $0 · Grant/award (A): 156,713 (derivative) @ $0EDGAR

Recent 8-K events — Tango Therapeutics, Inc.

FiledFormItems reportedSource
2026-08-118-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-118-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-078-K/A5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-068-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2026-06-238-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-108-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-088-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-048-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2026-05-138-K2.02 — Results of Operations and Financial Condition
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
2026-05-088-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=TNGX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →